Click here to get full coverage on New once-daily pill gets FDA Breakthrough Therapy designation for NT1 - Stock Titan

New once-daily pill gets FDA Breakthrough Therapy designation for NT1  Stock Titan

New once-daily pill gets FDA Breakthrough Therapy designation for NT1 - Stock Titan

Click here to get full coverage on Alkermes plc Granted Breakthrough Therapy Designation for Alixorexton - TradingView — Track All Markets

Alkermes plc Granted Breakthrough Therapy Designation for Alixorexton  TradingView — Track All Markets

Alkermes plc Granted Breakthrough Therapy Designation for Alixorexton - TradingView — Track All Markets

Click here to get full coverage on Alkermes plc Reports Third Quarter 2025 Financial Results - PR Newswire

Alkermes plc Reports Third Quarter 2025 Financial Results  PR Newswire

Alkermes plc Reports Third Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Why Analysts are Rating Alkermes (ALKS) a Buy - Yahoo Finance

Why Analysts are Rating Alkermes (ALKS) a Buy  Yahoo Finance

Why Analysts are Rating Alkermes (ALKS) a Buy - Yahoo Finance

Click here to get full coverage on Orexin Receptor Agent ALKS 2680 Meets End Points in Phase 2 VIBRANCE-1 Study - NeurologyLive

Orexin Receptor Agent ALKS 2680 Meets End Points in Phase 2 VIBRANCE-1 Study  NeurologyLive

Orexin Receptor Agent ALKS 2680 Meets End Points in Phase 2 VIBRANCE-1 Study - NeurologyLive

Click here to get full coverage on Alkermes (NASDAQ:ALKS) EVP Sells $112,000.00 in Stock - MarketBeat

Alkermes (NASDAQ:ALKS) EVP Sells $112,000.00 in Stock  MarketBeat

Alkermes (NASDAQ:ALKS) EVP Sells $112,000.00 in Stock - MarketBeat

Click here to get full coverage on Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS) - GuruFocus

Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS)  GuruFocus

Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS) - GuruFocus

Click here to get full coverage on Brigita Anna Alks Obituary August 8, 2025 - Lombardo Funeral Home

Brigita Anna Alks Obituary August 8, 2025  Lombardo Funeral Home

Brigita Anna Alks Obituary August 8, 2025 - Lombardo Funeral Home

Click here to get full coverage on Alkermes plc Reports Second Quarter 2025 Financial Results - PR Newswire

Alkermes plc Reports Second Quarter 2025 Financial Results  PR Newswire

Alkermes plc Reports Second Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Alkermes rises as narcolepsy drug gets FDA breakthrough tag - TradingView — Track All Markets

Alkermes rises as narcolepsy drug gets FDA breakthrough tag  TradingView — Track All Markets

Alkermes rises as narcolepsy drug gets FDA breakthrough tag - TradingView — Track All Markets

Click here to get full coverage on Analysts Just Made An Incredible Upgrade To Their Alkermes plc (NASDAQ:ALKS) Forecasts - Yahoo Finance

Analysts Just Made An Incredible Upgrade To Their Alkermes plc (NASDAQ:ALKS) Forecasts  Yahoo Finance

Analysts Just Made An Incredible Upgrade To Their Alkermes plc (NASDAQ:ALKS) Forecasts - Yahoo Finance

Click here to get full coverage on Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD - NeurologyLive

Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD  NeurologyLive

Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD - NeurologyLive

Click here to get full coverage on Alkermes Response to Avadel Announcement - PR Newswire

Alkermes Response to Avadel Announcement  PR Newswire

Alkermes Response to Avadel Announcement - PR Newswire

Click here to get full coverage on Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say  Yahoo Finance

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Click here to get full coverage on Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 - PR Newswire

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025  PR Newswire

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 - PR Newswire

Click here to get full coverage on Alkermes Appoints Joshua Reed as Chief Financial Officer - PR Newswire

Alkermes Appoints Joshua Reed as Chief Financial Officer  PR Newswire

Alkermes Appoints Joshua Reed as Chief Financial Officer - PR Newswire

Click here to get full coverage on Alkermes plc Reports First Quarter 2025 Financial Results - PR Newswire

Alkermes plc Reports First Quarter 2025 Financial Results  PR Newswire

Alkermes plc Reports First Quarter 2025 Financial Results - PR Newswire

Click here to get full coverage on Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - PR Newswire

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025  PR Newswire

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025 - PR Newswire

Click here to get full coverage on Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - PR Newswire

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia  PR Newswire

Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - PR Newswire

Click here to get full coverage on Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1  PR Newswire

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire

Click here to get full coverage on Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?  Yahoo Finance

Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Click here to get full coverage on Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result - Yahoo Finance

Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result  Yahoo Finance

Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result - Yahoo Finance

Click here to get full coverage on Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia - NeurologyLive

Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia  NeurologyLive

Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia - NeurologyLive

Click here to get full coverage on Should Alkermes (ALKS) Investors Reassess Prospects After Raised 2025 Guidance and Strong Q3 Results? - Yahoo Finance

Should Alkermes (ALKS) Investors Reassess Prospects After Raised 2025 Guidance and Strong Q3 Results?  Yahoo Finance

Should Alkermes (ALKS) Investors Reassess Prospects After Raised 2025 Guidance and Strong Q3 Results? - Yahoo Finance

Click here to get full coverage on Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference  Business Wire

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire

Click here to get full coverage on ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - Yahoo Finance

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition  Yahoo Finance

ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - Yahoo Finance

Click here to get full coverage on Frazier Life Sciences Management L.P. Boosts Stock Position in Alkermes plc $ALKS - MarketBeat

Frazier Life Sciences Management L.P. Boosts Stock Position in Alkermes plc $ALKS  MarketBeat

Frazier Life Sciences Management L.P. Boosts Stock Position in Alkermes plc $ALKS - MarketBeat

Click here to get full coverage on Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - Yahoo Finance

Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion  Yahoo Finance

Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - Yahoo Finance

Click here to get full coverage on $ALKS stock is down 18% today. Here's what we see in our data. | ALKS Stock News - Quiver Quantitative

$ALKS stock is down 18% today. Here's what we see in our data. | ALKS Stock News  Quiver Quantitative

$ALKS stock is down 18% today. Here's what we see in our data. | ALKS Stock News - Quiver Quantitative

Click here to get full coverage on Alkermes (ALKS) Margin Decline Reinforces Cautious Outlook Despite Discounted Valuation - Yahoo Finance

Alkermes (ALKS) Margin Decline Reinforces Cautious Outlook Despite Discounted Valuation  Yahoo Finance

Alkermes (ALKS) Margin Decline Reinforces Cautious Outlook Despite Discounted Valuation - Yahoo Finance

Click here to get full coverage on Can Alkermes (ALKS) Overcome Modest Differentiation to Lead in Narcolepsy Treatment Innovation? - Yahoo Finance

Can Alkermes (ALKS) Overcome Modest Differentiation to Lead in Narcolepsy Treatment Innovation?  Yahoo Finance

Can Alkermes (ALKS) Overcome Modest Differentiation to Lead in Narcolepsy Treatment Innovation? - Yahoo Finance

Click here to get full coverage on Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences - PR Newswire

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences  PR Newswire

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences - PR Newswire

Click here to get full coverage on Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect? - Yahoo Finance

Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect?  Yahoo Finance

Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect? - Yahoo Finance

Click here to get full coverage on ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Yahoo Finance

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal  Yahoo Finance

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Yahoo Finance

Click here to get full coverage on Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc - PR Newswire

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc  PR Newswire

Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc - PR Newswire

Click here to get full coverage on Pacer Advisors Inc. Sells 98,825 Shares of Alkermes plc $ALKS - MarketBeat

Pacer Advisors Inc. Sells 98,825 Shares of Alkermes plc $ALKS  MarketBeat

Pacer Advisors Inc. Sells 98,825 Shares of Alkermes plc $ALKS - MarketBeat

Click here to get full coverage on Alkermes plc $ALKS Shares Sold by Rice Hall James & Associates LLC - MarketBeat

Alkermes plc $ALKS Shares Sold by Rice Hall James & Associates LLC  MarketBeat

Alkermes plc $ALKS Shares Sold by Rice Hall James & Associates LLC - MarketBeat

Click here to get full coverage on How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% - Yahoo Finance

How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19%  Yahoo Finance

How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% - Yahoo Finance

Click here to get full coverage on First Week of ALKS August 2026 Options Trading - Nasdaq

First Week of ALKS August 2026 Options Trading  Nasdaq

First Week of ALKS August 2026 Options Trading - Nasdaq

Click here to get full coverage on ALKERMES Earnings Results: $ALKS Reports Quarterly Earnings - Quiver Quantitative

ALKERMES Earnings Results: $ALKS Reports Quarterly Earnings  Quiver Quantitative

ALKERMES Earnings Results: $ALKS Reports Quarterly Earnings - Quiver Quantitative

Click here to get full coverage on Trading the Move, Not the Narrative: (ALKS) Edition - Stock Traders Daily

Trading the Move, Not the Narrative: (ALKS) Edition  Stock Traders Daily

Trading the Move, Not the Narrative: (ALKS) Edition - Stock Traders Daily

Click here to get full coverage on Alkermes Gains FDA Breakthrough Status for Narcolepsy Drug - TipRanks

Alkermes Gains FDA Breakthrough Status for Narcolepsy Drug  TipRanks

Alkermes Gains FDA Breakthrough Status for Narcolepsy Drug - TipRanks

Click here to get full coverage on ALKS or ILMN: Which Is the Better Value Stock Right Now? - Nasdaq

ALKS or ILMN: Which Is the Better Value Stock Right Now?  Nasdaq

ALKS or ILMN: Which Is the Better Value Stock Right Now? - Nasdaq

Click here to get full coverage on Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program - PR Newswire

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program  PR Newswire

Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program - PR Newswire

Click here to get full coverage on Alkermes (ALKS): Evaluating Valuation After Promising Vibrance-2 Narcolepsy Drug Results - Sahm

Alkermes (ALKS): Evaluating Valuation After Promising Vibrance-2 Narcolepsy Drug Results  Sahm

Alkermes (ALKS): Evaluating Valuation After Promising Vibrance-2 Narcolepsy Drug Results - Sahm

Click here to get full coverage on Alkermes falls after mid-stage trial data for sleep therapy - Seeking Alpha

Alkermes falls after mid-stage trial data for sleep therapy  Seeking Alpha

Alkermes falls after mid-stage trial data for sleep therapy - Seeking Alpha

Click here to get full coverage on ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - Yahoo Finance

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study  Yahoo Finance

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - Yahoo Finance

Click here to get full coverage on ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Zacks Investment Research

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal  Zacks Investment Research

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Zacks Investment Research

Click here to get full coverage on Insider Sale: EVP R&D of $ALKS Sells 9,000 Shares - Quiver Quantitative

Insider Sale: EVP R&D of $ALKS Sells 9,000 Shares  Quiver Quantitative

Insider Sale: EVP R&D of $ALKS Sells 9,000 Shares - Quiver Quantitative

Click here to get full coverage on A Look at Alkermes (ALKS) Valuation Following Q3 Earnings Beat and Raised 2025 Outlook - simplywall.st

A Look at Alkermes (ALKS) Valuation Following Q3 Earnings Beat and Raised 2025 Outlook  simplywall.st

A Look at Alkermes (ALKS) Valuation Following Q3 Earnings Beat and Raised 2025 Outlook - simplywall.st

Click here to get full coverage on Wall Street Analysts Predict a 34.8% Upside in Alkermes (ALKS): Here's What You Should Know - Nasdaq

Wall Street Analysts Predict a 34.8% Upside in Alkermes (ALKS): Here's What You Should Know  Nasdaq

Wall Street Analysts Predict a 34.8% Upside in Alkermes (ALKS): Here's What You Should Know - Nasdaq

Click here to get full coverage on Alkermes (ALKS) Shares Decline Over 10% - GuruFocus

Alkermes (ALKS) Shares Decline Over 10%  GuruFocus

Alkermes (ALKS) Shares Decline Over 10% - GuruFocus

Click here to get full coverage on Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - Yahoo Finance

Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia  Yahoo Finance

Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - Yahoo Finance

Click here to get full coverage on A New Buyout Battle Is Brewing In Biotech; One Stock Is Up 20% - Investor's Business Daily

A New Buyout Battle Is Brewing In Biotech; One Stock Is Up 20%  Investor's Business Daily

A New Buyout Battle Is Brewing In Biotech; One Stock Is Up 20% - Investor's Business Daily

Click here to get full coverage on ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - TradingView — Track All Markets

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal  TradingView — Track All Markets

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - TradingView — Track All Markets

Click here to get full coverage on EcoR1 Capital LLC Makes New Investment in Alkermes plc $ALKS - MarketBeat

EcoR1 Capital LLC Makes New Investment in Alkermes plc $ALKS  MarketBeat

EcoR1 Capital LLC Makes New Investment in Alkermes plc $ALKS - MarketBeat

Click here to get full coverage on Alkermes: A More Than Solid Quarter (NASDAQ:ALKS) - Seeking Alpha

Alkermes: A More Than Solid Quarter (NASDAQ:ALKS)  Seeking Alpha

Alkermes: A More Than Solid Quarter (NASDAQ:ALKS) - Seeking Alpha

Click here to get full coverage on Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result - GuruFocus

Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result  GuruFocus

Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result - GuruFocus

Click here to get full coverage on Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo Finance

Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ...  Yahoo Finance

Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo Finance

Click here to get full coverage on Brigita Alks Obituary (1942 - 2025) - Buffalo, NY - Buffalo News - Legacy | Obituary

Brigita Alks Obituary (1942 - 2025) - Buffalo, NY - Buffalo News  Legacy | Obituary

Brigita Alks Obituary (1942 - 2025) - Buffalo, NY - Buffalo News - Legacy | Obituary

Click here to get full coverage on Is Alkermes Plc (NASDAQ:ALKS) Trading At A 43% Discount? - 富途牛牛

Is Alkermes Plc (NASDAQ:ALKS) Trading At A 43% Discount?  富途牛牛

Is Alkermes Plc (NASDAQ:ALKS) Trading At A 43% Discount? - 富途牛牛

Click here to get full coverage on Alkermes (ALKS) Faces Potential Termination of Acquisition Agree - GuruFocus

Alkermes (ALKS) Faces Potential Termination of Acquisition Agree  GuruFocus

Alkermes (ALKS) Faces Potential Termination of Acquisition Agree - GuruFocus

Click here to get full coverage on Alkermes (ALKS) Shares Fall Despite Positive Trial Results for S - GuruFocus

Alkermes (ALKS) Shares Fall Despite Positive Trial Results for S  GuruFocus

Alkermes (ALKS) Shares Fall Despite Positive Trial Results for S - GuruFocus

Click here to get full coverage on Avadel board backs Alkermes' higher offer over Lundbeck proposal - Reuters

Avadel board backs Alkermes' higher offer over Lundbeck proposal  Reuters

Avadel board backs Alkermes' higher offer over Lundbeck proposal - Reuters

Click here to get full coverage on ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - MSN

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal  MSN

ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - MSN

Click here to get full coverage on TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment - Insider Monkey

TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment  Insider Monkey

TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment - Insider Monkey

Click here to get full coverage on Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free Milestone - Yahoo Finance

Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free Milestone  Yahoo Finance

ALKS

Price Chart

Key Statistics

Technicals

About ALKS

Latest News

New once-daily pill gets FDA Breakthrough Therapy designation for NT1 - Stock Titan

Alkermes plc Granted Breakthrough Therapy Designation for Alixorexton - TradingView — Track All Markets

Alkermes plc Reports Third Quarter 2025 Financial Results - PR Newswire

Advanced Charts

Top Gainers

Top Losers